SCHEMBL2947669

SCHEMBL2947669

COC(=O)c1cccc(OCC(=O)Nc2ccc(Cl)cn2)c1C#N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
RAB9A P51151 4/20 0.59
NPC1 O15118 3/20 0.59
TP53 P04637 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
MAPT P10636 5/20 0.54
TSHR P16473 3/20 0.54
MAPK1 P28482 2/20 0.54
PKM P14618 1/20 0.54
HPGD P15428 1/20 0.54
ALDH1A1 P00352 5/20 0.52
NPSR1 Q6W5P4 1/20 0.49
KDM4E B2RXH2 3/20 0.48
TDP1 Q9NUW8 1/20 0.46
POLB P06746 1/20 0.45
SAE1 Q9UBE0 1/20 0.45
UBA2 Q9UBT2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947927 0.86 RAB9A (0.72) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL2953398 0.80 RAB9A (0.59) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL2942298 0.79 RAB9A (0.72) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL13665151 0.78 LMNA (0.59) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL2950658 0.78 RAB9A (0.57) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL2940082 0.78 RAB9A (0.59) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL2950227 0.78 RAB9A (0.56) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL13291200 0.78 RAB9A (0.56) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL13291208 0.78 RAB9A (0.56) LMNARAB9ANPC1TP53SMN1; SMN2
SCHEMBL2945526 0.78 RAB9A (0.65) LMNARAB9ANPC1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1489078-B1 BENZOFURAN DERIVATIVE MITSUBISHI TANABE PHARMA CORP (JP) 2010-01-06 EP disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 US disclosed
US-7531537-B2 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-12 US disclosed
US-20060247273-A1 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-11-02 US disclosed
EP-1666478-A1 CARBAMOYL-TYPE BENZOFURAN DERIVATIVES TANABE SEIYAKU CO., LTD. (JP) 2006-06-07 EP disclosed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 US disclosed
EP-1489078-A1 BENZOFURAN DERIVATIVE Tanabe Seiyaku Co., Ltd. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282808-A1 Benzofuran derivative F12, F2, F11 LMNA 3104/4885RAB9A 4616/4885NPC1 3519/4885
US-20060247273-A1 Carbamoyl-type benzofuran derivatives F12, F2, F3 LMNA 3286/4885RAB9A 2276/4885NPC1 3578/4885
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 LMNA 2928/4885RAB9A 4600/4885NPC1 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.